(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
-0.09% $ 34.06
@ $37.88
Wydano: 14 vas. 2024 @ 16:30
Zwrot: -10.08%
Poprzedni sygnał: vas. 13 - 16:30
Poprzedni sygnał:
Zwrot: 2.07 %
Live Chart Being Loaded With Signals
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency...
Stats | |
---|---|
Dzisiejszy wolumen | 189 853 |
Średni wolumen | 477 452 |
Kapitalizacja rynkowa | 1.61B |
EPS | $0 ( 2024-03-04 ) |
Następna data zysków | ( $-1.040 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.65 |
ATR14 | $0.0100 (0.03%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-26 | Deck Kelly | Sell | 625 | Stock Option (right to buy) |
2024-03-26 | Deck Kelly | Sell | 396 | Stock Option (right to buy) |
2024-03-26 | Deck Kelly | Sell | 1 459 | Stock Option (right to buy) |
2024-03-26 | Deck Kelly | Sell | 416 | Stock Option (right to buy) |
2024-03-20 | Deck Kelly | Sell | 16 777 | Stock Option (right to buy) |
INSIDER POWER |
---|
56.17 |
Last 100 transactions |
Buy: 3 248 725 | Sell: 1 114 859 |
Wolumen Korelacja
Inhibrx, Inc. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
BIOC | 0.929 |
NCBS | 0.92 |
FSFG | 0.918 |
SNPX | 0.911 |
SPFI | 0.906 |
BGFV | 0.905 |
EQBK | 0.905 |
SGMA | 0.904 |
PDBC | 0.903 |
ADTX | 0.903 |
10 Najbardziej negatywne korelacje | |
---|---|
GDNR | -0.918 |
BTWN | -0.917 |
EZGO | -0.906 |
LUNA | -0.904 |
BRAC | -0.903 |
MLCO | -0.902 |
MLVF | -0.902 |
AVAC | -0.902 |
CBAY | -0.9 |
IIN | -0.899 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Inhibrx, Inc. Korelacja - Waluta/Towar
Inhibrx, Inc. Finanse
Annual | 2023 |
Przychody: | $1.80M |
Zysk brutto: | $609 000 (33.83 %) |
EPS: | $-5.12 |
FY | 2023 |
Przychody: | $1.80M |
Zysk brutto: | $609 000 (33.83 %) |
EPS: | $-5.12 |
FY | 2022 |
Przychody: | $2.18M |
Zysk brutto: | $-668 000 (-30.67 %) |
EPS: | $-3.62 |
FY | 2021 |
Przychody: | $7.13M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2.15 |
Financial Reports:
No articles found.
Inhibrx, Inc.
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej